Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline

The effects of OATP1B1, OAT3, and MRP2 on the pharmacokinetics of eluxadoline, an oral, locally active, opioid receptor agonist/antagonist being developed for treatment of IBS‐d were assessed in vivo. Coadministration of a single 200 mg dose of eluxadoline with cyclosporine, and probenecid increased...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacology 2015-05, Vol.55 (5), p.534-542
Main Authors: Davenport, J. Michael, Covington, Paul, Bonifacio, Laura, McIntyre, Gail, Venitz, Jürgen
Format: Article
Language:English
Subjects:
Adult
Area Under Curve
Cross-Over Studies
cyclosporine
Cyclosporine - pharmacology
drug interaction
eluxadoline
Half-Life
Humans
Imidazoles - administration & dosage
Imidazoles - adverse effects
Imidazoles - pharmacokinetics
Metabolic Clearance Rate
Middle Aged
Multidrug Resistance-Associated Proteins - metabolism
Organic Anion Transporters - metabolism
Organic Anion Transporters, Sodium-Independent - metabolism
Pharmacogenomics
pharmacokinetics
Phenylalanine - administration & dosage
Phenylalanine - adverse effects
Phenylalanine - analogs & derivatives
Phenylalanine - pharmacokinetics
probenecid
Probenecid - pharmacology
Solute Carrier Organic Anion Transporter Family Member 1b1
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effects of OATP1B1, OAT3, and MRP2 on the pharmacokinetics of eluxadoline, an oral, locally active, opioid receptor agonist/antagonist being developed for treatment of IBS‐d were assessed in vivo. Coadministration of a single 200 mg dose of eluxadoline with cyclosporine, and probenecid increased eluxadoline systemic exposure [AUC(0–inf)] by 4.4‐ and 1.4‐fold, respectively, whereas peak exposure (Cmax) increased 6.2‐fold and 1.3‐fold, respectively. Cyclosporine had little effect on renal clearance (CLren) of eluxadoline whereas probenecid reduced CLren by nearly 50%. These study results suggested that sinusoidal OATP1B1‐mediated hepatic uptake of eluxadoline (during first‐pass and systemic extraction) plays a major role in its absorption and disposition, whereas OAT3‐mediated basolateral uptake in the proximal renal tubules and MRP2‐mediated canalicular and renal tubular apical efflux play only minor roles in its overall disposition. All treatments were safe and well tolerated.
ISSN:0091-2700
1552-4604
DOI:10.1002/jcph.442